PROCEPT BioRobotics faces securities fraud suit after 18% stock drop

PROCEPT BioRobotics faces a securities fraud class action over an undisclosed discount program that inflated handpiece sales, after shares fell more than 18% on a February inventory disclosure.

"When companies fail to disclose material information, shareholders may suffer significant losses," Joseph E. Levi, founding partner at Levi & Korsinsky, said. "The complaint asserts that PRCT investors paid prices that did not reflect alleged discounting and inventory risks tied to handpiece sales."

The lawsuit, filed in the US District Court for the Northern District of California, covers investors who bought PROCEPT common stock between February 28, 2024 and February 25, 2026. It alleges handpiece sales exceeded actual procedures by 8% to 16% every quarter since the first quarter of 2023, leaving cumulative excess field inventory of more than 10,000 units. The company disclosed on February 25 that quarterly US handpiece unit sales fell to 9,400 from 13,225 in the third quarter, a sequential decline of nearly 30%, and that it missed annual revenue guidance by tens of millions of dollars.

PROCEPT shares fell from $27.84 on February 25 to $22.69 on February 27, a drop of more than 18% over two trading days on above-average volume. The stock had traded as high as about $100 during the class period before settling below $25, a loss of more than $75 a share, or more than 75%. Investors seeking to serve as lead plaintiff must file papers by September 22, 2026. The case is Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691.

Bernstein Liebhard, Rosen Law Firm, Kahn Swick & Foti and Bleichmar Fonti & Auld have also announced investor actions tied to the same class period, each pointing to the discount-driven bulk ordering as the core of the alleged misstatements. The disclosure upends the recurring-revenue thesis that supported PROCEPT's valuation, since bulk discount orders pulled forward sales at the expense of future periods. Investors will watch for the court's lead-plaintiff appointment and any subsequent settlement or dismissal motions as the litigation proceeds.

This article is for informational purposes only and does not constitute investment advice.